NRX Pharmaceuticals, Inc. Accounts Payable
NRX Pharmaceuticals, Inc. (NRXP) had Accounts Payable of $3.15 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-14
- 2026-06-30: Accounts Payable, Current $3.15M.
- 2026-03-31: Accounts Payable, Current $4.40M.
- 2025-12-31: Accounts Payable, Current $4.27M.
- 2025-09-30: Accounts Payable, Current $4.26M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $3.15M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $4.40M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $4.27M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $4.26M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $3.63M 10-Q · filed 2025-08-18 |
| 2025-03-31 | $4.31M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $4.13M 10-K · filed 2026-03-23 |
| 2024-09-30 | $4.87M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.01M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $6.26M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.63M 10-K · filed 2025-03-14 |
| 2023-09-30 | $3.63M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.21M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $3.78M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.08M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.17M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.08M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $4.31M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $3.69M 10-K · filed 2023-03-31 |
| 2021-09-30 | $5.56M 10-Q/A · filed 2022-08-12 |
| 2021-06-30 | $6.27M 10-Q/A · filed 2022-08-12 |
| 2020-12-31 | $3.15M 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |